(Q32143825)

6 July 2017

1 reference

title

Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data (English)

1 reference

6 July 2017

0 references

2

Ralph Brattsand

1 reference

6 July 2017

Staffan Edsbäcker

1

1 reference

6 July 2017

publication date

1 June 2002

1 reference

Annals of Allergy, Asthma & Immunology

6 July 2017

published in

1 reference

6 July 2017

volume

88

1 reference

6 July 2017

issue

6

1 reference

6 July 2017

page(s)

609-616

1 reference

Rationale for once-daily therapy in asthma: compliance issues

6 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Detection in bovine adrenal cortex of a lipoidal substance that yields pregnenolone upon treatment with alkali

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

The naturally occurring C-17 fatty acid esters of estradiol are long-acting estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Molecular mechanisms of intracellular cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Biological esterification of steroids.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Pulmonary disposition of the potent glucocorticoid budesonide, evaluated in an isolated perfused rat lung model

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line In vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Prolonged airway activity and improved selectivity of budesonide possibly due to esterification

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Relationship between lung tissue and blood plasma concentrations of inhaled budesonide

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Nasal retention of budesonide and fluticasone in man: formation of airway mucosal budesonide-esters in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Effects of high-dose inhaled corticosteroids on plasma cortisol concentrations in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

Effect of long-term treatment with inhaled budesonide on adult height in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

A review of budesonide inhalation suspension in the treatment of pediatric asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961893-5

7 January 2021

10.1016/S1081-1206(10)61893-5

Identifiers

DOI

1 reference

6 July 2017

1 reference